Skip to main
INBX

INBX Stock Forecast & Price Target

INBX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inhibrx Biosciences Inc is positioned favorably with $186.6 million in cash, providing substantial capital for the continued development of its key therapeutic candidates, INBRX-109 and INBRX-106, with critical readouts anticipated in the fourth quarter of 2025. The company’s proprietary single-domain antibody and protein engineering platforms present long-term value potential, enhancing the attractiveness of its innovative drug pipeline. Additionally, Inhibrx generated revenue of $1.3 million in the second quarter of 2025 from a license agreement with Regeneron Pharmaceuticals, indicating ongoing commercial collaboration and financial stability.

Bears say

Inhibrx Biosciences faces a negative outlook primarily due to the potential for stock price declines even if the company meets investor expectations, indicating underlying market concerns beyond performance metrics. Additionally, the risk of failure to achieve regulatory approval or experiencing delays in approval timelines poses a significant threat to the company's share price, highlighting uncertainty in the approval landscape for its clinical candidates. Furthermore, the variance in Research and Development expenses, reported at $22.3 million compared to the estimated $36.9 million, raises concerns about the adequacy of investment in key developmental areas, potentially jeopardizing future product initiatives and growth.

INBX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inhibrx Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inhibrx Biosciences Inc (INBX) Forecast

Analysts have given INBX a Strong Buy based on their latest research and market trends.

According to 1 analysts, INBX has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $150, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $150, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inhibrx Biosciences Inc (INBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.